ArticleCancer2018
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- HER2 expression in urothelial carcinoma, a systematic literature review.Frontiers in oncology · 2022Pooled it
- Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial.Frontiers in immunology · 2026Trial
- Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).BMC cancer · 2021Trial
- Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers.Frontiers in oncology · 2026Review
- Absence of bladder cancer cells in surgical smoke from robot-assisted radical cystectomy: a prospective study.Frontiers in urology · 2026Article
- Genomic alteration and clinical significance of circulating tumor DNA in patients with advanced urothelial cancer: SCRUM-Japan monstar screen project.NPJ precision oncology · 2025Article
- Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer.Current treatment options in oncology · 2025Review
- Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation.Nature reviews. Urology · 2025Review
- Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.Nature reviews. Urology · 2025Review
- Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder.Current oncology reports · 2025Review
- Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review.Cancers · 2024Review
- Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications.Cancers · 2024Review
- NTRK3 exhibits a pro-oncogenic function in upper tract urothelial carcinomas.The Kaohsiung journal of medical sciences · 2024Article
- Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.Molecules (Basel, Switzerland) · 2024Review
- Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.World journal of urology · 2023Article
- Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.Scientific reports · 2023Article
- Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.Nature reviews. Urology · 2023Review
- Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.Molecular oncology · 2022Article
- Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma.Cancers · 2022Article
- Circulating tumor cells and cell-free tumor DNA analyses in urothelial cancer using the LiquidBiopsy platform.Current urology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 16 institutions in 2 countries.
Funding
Abstract
backgroundBiomarker-guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not available are not eligible. Technological advancements in sequencing have made cell-free circulating DNA (cfDNA) next-generation sequencing (NGS) readily available in the clinic. The objective of the current study was to determine whether the genomic profile of mUC detected by NGS of cfDNA is similar to historical tumor tissue NGS studies. A secondary objective was to determine whether the frequency of genomic alterations (GAs) differed between lower tract mUC (mLTUC) and upper tract mUC (mUTUC).
methodsPatients from 13 academic medical centers in the United States who had a diagnosis of mUC between 2014 and 2017 and for whom cfDNA NGS results were available were included. cfDNA profiling was performed using a commercially available platform (Guardant360) targeting 73 genes.
resultsOf 369 patients with mUC, 294 were diagnosed with mLTUC and 75 with mUTUC. A total of 2130 GAs were identified in the overall mUC cohort: 1610 and 520, respectively, in the mLTUC and mUTUC cohorts. In the mLTUC cohort, frequently observed GAs were similar between cfDNA NGS and historical tumor tissue studies, including tumor protein p53 (TP53) (P = 1.000 and .115, respectively), AT-rich interaction domain 1A (ARID1A) (P = .058 and .058, respectively), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (P = .058 and .067, respectively), erb-b2 receptor tyrosine kinase 2 (ERBB2) (P = .565 and .074, respectively), and fibroblast growth factor receptor 3 (FGFR3) (P = .164 and .014, respectively). No significant difference was observed with regard to the frequency of GAs between patients with mLTUC and mUTUC.
conclusionsAmong patients with mUC for whom no tumor tissue was available, cfDNA NGS was able to identify a similar profile of GAs for biomarker-driven clinical trials compared with tumor tissue. Despite the more aggressive clinical course, cases of mUTUC demonstrated a circulating tumor DNA genomic landscape that was similar to that of mLTUC. Cancer 2018;124:2115-24. © 2018 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.